Quick Answer
Prelude Therapeutics Inc reported Stockholders Equity of $68.64 million for the year ending 2025.
- Prelude Therapeutics Inc showed a decrease of -47.8% in Stockholders Equity from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$27.85 million | Q2 2019: -$33.26 million | Q3 2019: -$39.70 million | Q1 2020: -$58.56 million | Q2 2020: -$69.31 million | Q3 2020: $228.31 million | Q1 2021: $356.57 million | Q2 2021: $334.36 million | Q3 2021: $311.24 million | Q1 2022: $261.81 million | Q2 2022: $240.84 million | Q3 2022: $217.41 million | Q1 2023: $175.30 million | Q2 2023: $262.06 million | Q3 2023: $238.26 million | Q1 2024: $210.73 million | Q2 2024: $182.28 million | Q3 2024: $156.43 million | Q1 2025: $103.18 million | Q2 2025: $75.84 million | Q3 2025: $58.53 million.
- Over the full 8 years of available data (2018 to 2025), Prelude Therapeutics Inc's Stockholders Equity has grown by 402.5%.
- Historical annual values: Fiscal year 2025: $68.64 million | Fiscal year 2024: $131.46 million | Fiscal year 2023: $237.09 million | Fiscal year 2022: $195.44 million | Fiscal year 2021: $285.90 million | Fiscal year 2020: $212.18 million | Fiscal year 2019: -$49.41 million | Fiscal year 2018: -$22.69 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: